Arbutus Biopharma Corporation (ABUS)
- Previous Close
2.7800 - Open
2.7800 - Bid 2.7000 x 200
- Ask 2.7500 x 1100
- Day's Range
2.6900 - 2.7900 - 52 Week Range
1.6900 - 3.2900 - Volume
988,339 - Avg. Volume
1,419,666 - Market Cap (intraday)
491.878M - Beta (5Y Monthly) 2.09
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4400 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.40
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
www.arbutusbio.comRecent News: ABUS
Performance Overview: ABUS
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABUS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABUS
Valuation Measures
Market Cap
493.68M
Enterprise Value
369.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
25.07
Price/Book (mrq)
4.66
Enterprise Value/Revenue
20.37
Enterprise Value/EBITDA
-5.20
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.70%
Return on Equity (ttm)
-59.99%
Revenue (ttm)
18.14M
Net Income Avi to Common (ttm)
-72.85M
Diluted EPS (ttm)
-0.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
126M
Total Debt/Equity (mrq)
8.23%
Levered Free Cash Flow (ttm)
-51.58M